Literature DB >> 30817035

Anaphylaxis after Elosulfase A infusion: Omalizumab as coadjuvant for enzyme replacement therapy desensitization.

Esozia Arroabarren1, Elena Aznal2, Marta Anda1, Felix Sanchez-Valverde2.   

Abstract

Entities:  

Keywords:  breakthrough reactions; child; desensitization; elosulfase; mucopolysaccharidosis IV A; omalizumab

Mesh：

Substances：

Year:  2019        PMID： 30817035     DOI： 10.1111/pai.13049

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN： 0905-6157            Impact factor:   6.377


× No keyword cloud information.
  2 in total

1.  Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study.

Authors:  Hanneke N G Oude Elberink; Mathilde Jalving; Hilda Dijkstra; Annick A J M van de Ven
Journal:  Clin Transl Allergy       Date:  2020-01-29       Impact factor: 5.871

Review 2.  Omalizumab for successful chemotherapy desensitisation: What we know so far.

Authors:  Roxana Silvia Bumbacea; Selda Ali; Sabina Loredana Corcea; Luiza Spiru; Cornelia Nitipir; Victor Strambu; Dragos Bumbacea
Journal:  Clin Transl Allergy       Date:  2021-12-13       Impact factor: 5.871
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.